Turning Point Brands Q2 Sales Surge 23%, Modern Oral Revenue Nearly Triples; Guidance Raised
TPB sits 27% above its 52-week low of $65.8.
Summary
Turning Point Brands reported Q2 sales of $143 million, beating estimates by 11%, driven by explosive growth in Modern Oral products. Full-year Modern Oral guidance was raised, but heavy spending on marketing and distribution caused net income to drop 75%.
Key Events · Earnings and Guidance · TPB
-
Q2 Sales Beat, Modern Oral Surges
Total net sales rose 22.6% to $142.9 million, exceeding the $129 million consensus. Modern Oral gross revenue jumped 149% to $87.0 million, now 48% of total net sales.
-
Full-Year Modern Oral Guidance Raised
Management lifted Modern Oral gross sales guidance to $330-$350 million (from $280-$300 million) and net sales to $260-$270 million (from $210-$225 million).
-
Profitability Compressed by Investment
Net income fell 75.2% to $3.6 million and Adjusted EBITDA declined 50% to $15.2 million, as SG&A expenses nearly doubled to $76.9 million to fund Modern Oral growth.
-
Equity Raise Bolsters Liquidity
The company raised $59.6 million in equity during the quarter, ending with $268.3 million in cash and total liquidity of $339.0 million.
Analysis · TPB · Manufacturing
A standout quarter saw total sales jump 23% to $143 million, well above the $129 million consensus. The Modern Oral segment is the clear growth engine — gross revenue nearly tripled to $87 million, now accounting for almost half of total company sales. Management raised full-year Modern Oral guidance significantly, signaling confidence in sustained momentum. However, heavy investments in sales and marketing to capture market share are compressing margins: net income fell 75% to $3.6 million and Adjusted EBITDA halved to $15.2 million. The company also raised $59.6 million in equity during the quarter, providing ample liquidity to fund expansion. The stock is reacting to the top-line beat and raised outlook, but the profit sacrifice warrants attention.
How filings like this one have moved
In the 30 days to Sep 23, 2026, 35.1% of the 1081 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TPB was trading at $83.50 on NYSE in the Manufacturing sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $65.80 to $146.90. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.